focus -WSS

focus

author：Wikipedia 2025-09-02 11:46:17 - browse：84634

CHICAGO — The Food and Drug Administration’s top oncologist reiterated that the agency doesn’t want drugmakers applying for approval with data from trials solely run in a single country such as China, but instead wants to see companies conducting studies across the world.

The comments by Richard Pazdur, director of the FDA’s Oncology Center of Excellence, came as more drugmakers report data from China, with Miami-based Summit Therapeutics earlier this week announcing that its investigational drug beat Merck’s blockbuster Keytruda in a head-to-head non-small cell lung cancer study in China.

It’s not a blanket policy, and the agency would assess each company’s submission to see how applicable the data are to the U.S. population, but in general, “I am pro multi-regional trials,” Pazdur said Friday at STAT@ASCO, STAT’s event at the American Society of Clinical Oncology annual meeting.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： STAT readers on older presidents, polypills, Medicare, and more

WSS

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

Doctors find melanoma drugs effective against rare brain cancer

Alabama IVF ruling threatens families facing fatal genetic disease

Google and Epic fight stronger regulation of AI in health care

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Obesity drugs seen as possible treatment for liver disease MASH

hotspot

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Jerome Adams on the need for new antivirals for Covid

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

Continuity nursing helped my family in our darkest PICU moments

How dance can help nurses traumatized by Covid

Cancer drug shortages should be causing more outrage

Ed Silverman on new gene therapies, biosimilars, coffee, and more

Duchenne breakthrough therapy leaves behind pioneering families

With competition flaring, obesity drug hits goal in liver disease study

At least 13 dead in Texas as scorching temps continue

6 phony surgeries that take placebo to the extreme

focus

Startup Neumora takes a novel depression drug to Phase 3

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

How dance can help nurses traumatized by Covid

Sanders adds drug shortage policies to pandemic preparedness bill

Medicare to cover more brain scans for Alzheimer’s patients

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Wikipedia

hotspot

hotspot

leisure time